Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...

Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise.

Insulin, which regulates blood glucose (sugar), is an example of a peptide hormone. Your body naturally produces the hormones GLP-1 and gastric inhibitory polypeptide receptor (GIP), known as ...

US -based pharmaceutical giant Eli Lilly recently launched its weight loss drug Mounjaro in India. Tirzepatide is the generic ...

Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...

US drug developer Palatin Technologies (NYSE American: PTN) announced that its BMT-801 Phase II obesity co-administration ...

The combination met its primary endpoint of percent weight loss following an 8-week treatment period.

OBJECTIVE Gastric bypass (GB ... Plasma levels of the incretin glucagon-like peptide 1 (GLP-1) are dramatically increased after GB, suggesting that its action contributes to alteration in ...

The company reported positive topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP ...